Pages that link to "Q418560"
Jump to navigation
Jump to search
The following pages link to ifosfamide (Q418560):
Displayed 50 items.
- World Health Organization Model List of Essential Medicines (Q37155) (← links)
- breast cancer (Q128581) (← links)
- ovarian cancer (Q172341) (← links)
- stomach cancer (Q189588) (← links)
- pancreatic cancer (Q212961) (← links)
- testicular cancer (Q324464) (← links)
- D-fructofuranose 6-phosphate (Q412043) (← links)
- chronic lymphocytic leukemia (Q1088156) (← links)
- Ewing sarcoma (Q1138580) (← links)
- diffuse large B-cell lymphoma (Q2626074) (← links)
- ICE chemotherapy regimen (Q5969522) (← links)
- lymphoid leukemia (Q6708277) (← links)
- lymphosarcoma (Q12284921) (← links)
- IFEX (Q17190774) (← links)
- IMEP (chemotherapy) (Q18014888) (← links)
- MINE (chemotherapy) (Q18029508) (← links)
- lung benign neoplasm (Q18556020) (← links)
- Hodgkin's lymphoma, mixed cellularity (Q18557991) (← links)
- spindle cell sarcoma (Q18975788) (← links)
- (Q5908951) (redirect page) (← links)
- Evaluation of a procedure for the simultaneous quantification of 4-ketocyclophosphamide, cyclophosphamide, and ifosfamide in human urine (Q23910644) (← links)
- Evaluation of a multiple sclerosis cluster among nurses in an inpatient oncology ward (Q23912471) (← links)
- Sampling and mass spectrometric analytical methods for five antineoplastic drugs in the healthcare environment (Q23914149) (← links)
- Evaluation of chemotherapy drug exposure at a veterinary teaching hospital in Michigan (Q23914231) (← links)
- Reduction in surface contamination with antineoplastic drugs in 22 hospital pharmacies in the US following implementation of a closed-system drug transfer device (Q23919324) (← links)
- Development of an HPLC method for simultaneous analysis of five antineoplastic agents (Q23920413) (← links)
- A new monitoring method using solid sorbent media for evaluation of airborne cyclophosphamide and other antineoplastic agents (Q23920414) (← links)
- Monitoring method for surface contamination caused by selected antineoplastic agents (Q23923245) (← links)
- Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients (Q24186938) (← links)
- Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients (Q24202196) (← links)
- Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients (Q24240032) (← links)
- Cyclophosphamide versus ifosfamide for paediatric and young adult bone and soft tissue sarcoma patients (Q24244618) (← links)
- Health hazard evaluation report: HETA-2011-0047-3143, multiple sclerosis cluster evaluation in an inpatient oncology ward - Wisconsin (Q24266781) (← links)
- Lista de NIOSH de antineoplásicos y otros fármacos tóxicos en entornos de atención médica, 2010 (Q24706974) (← links)
- Health hazard evaluation report: HETA-2009-0148-3158, chemotherapy drug exposures at an oncology clinic - Florida (Q25018194) (← links)
- Health hazard evaluation report: HETA-2010-0068-3156, chemotherapy drug evaluation at a veterinary teaching hospital - Michigan (Q25892070) (← links)
- NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2010 (Q26376049) (← links)
- Microencapsulated, CYP2B1-transfected cells activating ifosfamide at the site of the tumor: the magic bullets of the 21st century (Q28202157) (← links)
- Mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) chemotherapy for gynecological sarcomas (Q28215648) (← links)
- (Q28250457) (← links)
- A prospective randomized phase III study in non-small-cell lung cancer comparing cisplatin, ifosfamide, vinblastine (VIP) versus cisplatin, ifosfamide and etoposide (VIP-16). Hellenic Co-Operative Oncology Group (Q28292151) (← links)
- Ifosfamide encephalopathy (Q28292704) (← links)
- VIP (etoposide, ifosfamide, cisplatin) in adult patients with recurrent or refractory Ewing sarcoma family of tumors (Q28298181) (← links)
- Mesna, doxorubicin, ifosfamide, dacarbazine (MAID) regimen for adults with advanced sarcoma (Q28299143) (← links)
- Ifosfamide or trofosfamide in patients with intraocular lymphoma (Q28304762) (← links)
- Ifosfamide, carboplatin and etoposide (ICE) combined with 41.8 degrees C whole body hyperthermia in patients with refractory sarcoma (Q28306616) (← links)
- Comparison of N-acetylcysteine and mesna as uroprotectors with ifosfamide combination chemotherapy in refractory germ cell tumors (Q28317221) (← links)
- An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma (Q28318141) (← links)
- Abnormalities in serum osteocalcin values in children receiving chemotherapy including ifosfamide (Q28318766) (← links)
- High-dose ifosfamide therapy: systemic use of a mucolytic agent for the reduction of urotoxicity (Q28319302) (← links)